Physician profile
Solimar Diaz
NPI 1366530842
$2,783.04
in general payments reported to CMS, 2019-2025
14 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $214 · 2021: $237 · 2022: $654 · 2023: $442 · 2024: $589 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,280.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $688.66 | 2019-2024 | Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $350.30 | 2019-2022 | |
| Lilly USA, LLC | $337.44 | 2023-2025 | Mounjaro, Zepbound |
| Teva Pharmaceuticals USA, INC. | $325.65 | 2019-2020 | |
| Abbott Laboratories | $267.14 | 2023 | Freestyle Libre 3 |
| Abbvie INC. | $242.73 | 2024-2025 | |
| Novo Nordisk INC | $169.81 | 2021-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $150.41 | 2019-2024 | Vaxneuvance, Gardasil, Gardasil 9 |
| Biohaven Pharmaceutical Holding Company LTD. | $75.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $72.43 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.70 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $21.01 | 2021 | |
| Pbg Puerto Rico LLC | $20.00 | 2023 | |
| Biocryst US Sales Co., LLC | $13.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Solimar Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.